Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease. (PIMPARK)

Study of Pimavanserin Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease

There is no consensus on the treatment of Impulse Control Disorder (ICD) in Parkinson Disease (PD) though it is recommended to reduce the dosage of dopamine agonists (DA).

Reduction of DA frequently leads to a worsening of motor signs (parkinsonism or dyskinesias due to the concomitant increase of levodopa doses) and non-motor signs with the appearance of a DA withdrawal syndrome (DAWS).

Chronic stimulation of the sub-thalamic nuclei may reduce ICD but is restricted to a minority of patients and cases of new-onset ICD symptoms post stimulation have been reported. The benefit of amantadine in pathological gambling is controversial and the efficacy of clozapine has been reported in a few cases but with serious safety limitations. Very recently, naltrexone did not significantly improve ICD.

Thus, an efficacious and safe treatment of ICD in PD remains an unmet need for clinical practice.

Recently, it has been reported that pimavanserin, a selective serotonin 5-HT2A inverse agonist with a satisfactory safety profile without motor side effects, was efficient in improving psychosis, insomnia and day-time sleep in PD.

Pimavanserin, marketed under the tradename NUPLAZID® was approved in 2016 by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

The link between serotonin and ICD has been well established, since the enhancement of 5HT2A receptors stimulation is associated to ICD, since serotonin modulates mesolimbic dopaminergic reward system transmission and given that serotonin neurotransmission is increased during chronic intake of dopamine agonist such as pramipexole which is well-known to induce ICD in PD patients. Thus, there is a large body of evidence suggesting that the decrease of the 5HT2A activity could be efficient in reducing ICD in PD. This further supports the concept of testing the efficacy of pimavanserin (a selective 5HT2A inverse agonist) for treating ICD in PD. Our aim is to conduct a study evaluating the efficacy and safety of pimavanserin on ICD in PD.

This clinical trial is conducted with the support of the French NS-Park/FCRIN (French Clinical Research Infrastructure Network) network.

Study Overview

• Status: Recruiting
• Conditions: Parkinson Disease
• Intervention / Treatment: Drug: Active drug: pimavanserin 17mg (2 strength tablets); Behavioral: Assessment of severity of ICD (impulse control disorders); Behavioral: Assessment of quality of life; Behavioral: Assessment of depression; Behavioral: Assessment of cognition; Behavioral: Assessment of severity of Parkinson Disease; Procedure: Blood analysis; Procedure: Cardiac monitoring; Drug: Placebo: 2 tablets containing same excipients except active compound; Behavioral: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors

• Study Type: Interventional
• Enrollment (Anticipated): 130
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Mathieu ANHEIM, MD; Phone Number: +33 3 88 12 85 35; Email: mathieu.anheim@chru-strasbourg.fr
• Study Contact Backup: Name: Olivier RASCOL, MD; Phone Number: +33 5 61 14 59 62; Email: olivier.rascol@univ-tlse3.fr

Study Locations

• France
  • Besançon, France
    • Recruiting
    • Service de Neurologie -CHU Besançon
    • Contact: Matthieu BEREAU, MD; Phone Number: +33 3 81 66 86 55; Email: mbereau@chu-besancon.fr
    • Principal Investigator: Matthieu BEREAU, MD
  • Bron, France, 69677
    • Recruiting
    • SERVICE DE NEUROLOGIE C, Unité mouvement anormaux/Centre expert Parkinson, CHU de Lyon, Hopital neurologique Pierre Wertheimer
    • Contact: Chloé LAURENCIN, MD; Phone Number: 33 4 72 35 72 35; Email: chloe.laurencin@chu-lyon.fr
    • Principal Investigator: Chloé LAURENCIN, MD
  • Clermont-Ferrand, France, 63003
    • Recruiting
    • SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson CHU Clermont-Ferrand, Hopital Gabriel Montpied
    • Contact: Ana MARQUES, MD; Phone Number: 33 4 73 75 22 00; Email: ar_marques@chu-clermontferrand.fr
    • Principal Investigator: Ana MARQUES, MD
  • Créteil, France, 94010
    • Recruiting
    • SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, Hopital Henri Mondor
    • Contact: Philippe REMY, MD; Phone Number: +33 1 49 81 43 53; Email: neuro-philippe.remy@hmn.aphp.fr
    • Principal Investigator: Philippe REMY, MD
  • Grenoble, France, 38043
    • Recruiting
    • SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CHU de Grenoble Alpes
    • Contact: Valérie FRAIX, MD; Phone Number: +33 4 76 76 94 52; Email: vfraix@chu-grenoble.fr
    • Principal Investigator: Valérie FRAIX, MD
  • Lille, France, 59037
    • Recruiting
    • SERVICE DE NEUROLOGIE, Unité Mouvement Anormaux/Centre expert Parkinson, CHU de Lille, Hopital Roger Salengro
    • Contact: Luc DEFEBVRE, MD; Phone Number: +33 3 20 44 67 30; Email: Luc.DEFEBVRE@CHRU-LILLE.FR
    • Principal Investigator: Luc DEFEBVRE, MD
  • Limoges, France, 87042
    • Recruiting
    • SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CHU de Limoges
    • Contact: Jean Luc HOUETO, MD; Phone Number: +33 5 55 05 65 60; Email: jean-luc.houeto@chu-limoges.fr
    • Principal Investigator: Jean-Luc HOUETO, MD
  • Marseille, France, 13385
    • Recruiting
    • SERVICE DE NEUROLOGIE, Unité Mouvement Anormaux/Centre expert Parkinson, Hopital de la Timone
    • Contact: Jean-Philippe AZULAY, MD; Phone Number: +33 4 91 38 43 33; Email: Jean-philippe.AZULAY@ap-hm.fr
    • Principal Investigator: Jean-Philippe AZULAY, MD
  • Nantes, France, 44093
    • Recruiting
    • SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CIC, CHU de Nantes, Hopital Laennec
    • Contact: Tiphaine ROUAUD, MD; Phone Number: +33 2 40 16 52 86; Email: Tiphaine.Rouaud@chu-nantes.fr
    • Principal Investigator: Tiphaine ROUAUD, MD
  • Paris, France, 75651
    • Recruiting
    • SERVICE DE NEUROLOGIE Centre Expert Parkinson Hopital de la Pitié-Salpêtrière
    • Contact: Jean-Christophe CORVOL, MD; Phone Number: +33 1 42 16 57 66; Email: jean-christophe.corvol@aphp.fr
    • Principal Investigator: Jean-Christophe CORVOL, MD
  • Poitiers, France, 86021
    • Recruiting
    • Centre d'Inverstigation Clinique, CHU de Poitiers
    • Contact: Isabelle BENATRU, MD; Phone Number: +33 5 49 44 44 46; Email: isabelle.benatru@chu-poitiers.fr
    • Principal Investigator: Isabelle BENATRU, MD
  • Reims, France, 51100
    • Recruiting
    • SERVICE DE NEUROLOGIE, CHU de REIMS
    • Contact: Anne DOE DE MAINDREVILLE, MD; Email: adoedemaindreville@chu-reims.fr
    • Principal Investigator: Anne DOE DE MAINDREVILLE, MD
  • Rennes, France, 35033
    • Recruiting
    • SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CHU de Rennes, Hopital Pontchaillou
    • Contact: Sophie DRAPIER, MD; Phone Number: +33 2 99 28 42 93; Email: Sophie.Drapier@chu-rennes.fr
    • Principal Investigator: Sophie DRAPIER, MD
  • Rouen, France, 76031
    • Recruiting
    • SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CHU de Rouen, Hopital Charles Nicolle
    • Contact: David MALTETE, MD; Phone Number: +33 2 32 88 87 40; Email: david.maltete@chu-rouen.fr
    • Principal Investigator: David MALTETE, MD
  • Strasbourg, France, 67098
    • Recruiting
    • SERVICE DE NEUROLOGIE Unité de Mouvements Anormaux/Centre expert Parkinson, CHU de Strasbourg, Hopital de Hautepierre
    • Principal Investigator: Mathieu Anheim, MD
    • Contact: Mathieu ANHEIM, MD; Phone Number: +33 3 88 12 85 35; Email: mathieu.anheim@chru-strasbourg.fr
  • Toulouse, France, 31059
    • Recruiting
    • SERVICE DE NEUROLOGIE, Unité Mouvements Anormaux/Centre expert Parkinson, CIC, CHU de Toulouse, Hopital Pierre-Paul Riquet
    • Principal Investigator: Olivier RASCOL, MD
    • Contact: Olivier RASCOL, MD; Phone Number: +33 5 61 14 59 62; Email: olivier.rascol@univ-tlse3.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 33 years to 73 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Patient with PD according to the UKPDSBB criteria for at least 1 year before randomization
2. Patient, man or woman, aged from 35 to 75 years old

3. Patient with moderately severe ICD assessed by QUIP-RS (each item being rated 0-16) defined as:

   • a combined ICD total score (defined as the sum of the 4 ICD sub-scores (pathological gambling + buying + hypersexuality + eating)) superior or equal to 10 or,

   • at least one of the 4 ICD sub-scores in the following range:

     1. "pathological gambling" sub-score from 6 to 12 (included),
     2. "buying" sub-score from 8 to 12 (included),
     3. "hypersexuality" sub-score from 8 to 12 (included),
     4. "eating" sub-score from 7 to 12 (included) (Weintraub et al., 2012). The use of "lower" margins will guarantee that the patient experiences behavioral disturbances severe enough to justify pimavanserin treatment. On the other hand, the use of "upper" margins will guarantee that the patients included in the trial will not suffer from ICD severe enough to question ethically the use of placebo during the 8 weeks of the treatment. Eligibility of patients with QUIP-RS sub-scores above 12 will be assessed upon investigator's request by an adjudication committee composed by independent experts external to the study (cf IX.3 Adjudication Committee).
4. ICD onset after PD onset and after initiation of dopaminergic drugs
5. Patient treated by dopaminergic drugs for at least 3 months before randomization
6. Patient treated with a stable regimen of levodopa, dopamine agonists, COMT and MAOB inhibitors, amantadine, anticholinergic, antidepressant and benzodiazepine for at least 1 month before the randomization and be willing to remain on the same doses throughout the course of their participation in the trial (Papay et al., 2014)
7. Patient with health insurance
8. Patient/ guardian / curator who sign the written informed consent
9. For women of childbearing potential, use of an effective contraception method* for at least 1 month prior to randomization until 8 weeks after the last dose of study drug administration. Women who do not have an effective contraception* must : have had her last natural menstruation ≥24 months prior to the selection visit, or have been surgically sterilized prior to the selection visit, or have had a hysterectomy prior to the selection visit.

Exclusion Criteria:

1. Patient suffering from another parkinsonian syndrome (multiple system atrophy, progressive supranuclear palsy, Lewy body dementia, corticobasal degeneration)
2. Patient who have a known hypersensitivity to the study treatment, based on known allergies to drugs of the same class
3. Stroke, uncontrolled serious medical illness, myocardial infarction, congestive heart failure, cardiac function disorders, within 6 months before randomization
4. Patient with history of long QT syndrome
5. Patient with long QTcB detected with ECG at inclusion visit (> 450 ms)
6. Patient treated with antipsychotic drugs during the last three months before randomization
7. Patient treated with concomitant medication leading to torsade de pointes (TdP) without discontinuation ≥ 5 half-lives before randomization (please refer to medications list with known risks of TdP on appendix XVII.5.10 and check website https://crediblemeds.org/index.php/tools/ for the most up-to-date information)

8. Patient with hydro-electrolytics troubles, particularly hypokaliemia or hypocalcemia not corrected, at inclusion visit or assessed no later than 8 days before randomization. To be eligible, the patient's electrolyte values should be within the following limits:

   3.5 ≤ K+ ≤ 5 mmol/L 135 ≤ Na+ ≤ 145 mmol/L 2,20 ≤ Ca2+ ≤ 2,60 mmol/L

9. Patient treated with a strong or moderate CYP3A4 inducer: carbamazepine, rifampicin, phenytoin, modafinil, efavirenz or a strong inhibitor of CYP3A4: azole antifungals, protease inhibitors, macrolids, without discontinuation ≥ 5 half-lives before randomization
10. Patient treated with medicinal plants interacting with CYP3A4 without discontinuation ≥ 5 half-lives before randomization (Echinacea (E.pupurea, E.angustifolia and E.pallida), Piperina, Artemisia, St. John's Wort and Ginkgo
11. Patient with Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) score < 20 (to exclude patients likely with dementia) at inclusion visit (Papay et al., 2014).
12. Patient suffering from severe depression or marked suicidal thoughts (score > 3 on the suicidal thoughts item of the MADRS) at inclusion visit (Papay et al., 2014)
13. History of DBS within the past year before randomization, or change in stimulation parameters less than one month prior to randomization

14. Hematologic or solid malignancy diagnosis within 5 years prior to randomization.

    [Note: Subjects with a history of localized skin cancer, basal cell or squamous cell carcinoma, may be enrolled in the study as long as they are cancer free prior to randomization. Subjects with other localized cancers (without metastatic spread) who have previously completed their course of treatment more than 5 years prior to randomization, are not currently receiving treatment and have been in remission may be enrolled only if, in the opinion of the Investigator, there is no expectation for recurrence or further cancer treatment during the study period. Antihormonal therapy (e.g., tamoxifen) is allowed if the subject's cancer is in remission and the subject is on stable maintenance therapy to reduce their risk of recurrence.]

15. Patient suffering from severe renal impairment define as CrCL<30 mL/min, Cockcroft-Gault at inclusion visit or assessed no later than 8 days before randomization
16. Clinically significant hepatic impairment
17. Concurrent participation in another research involving a drug or medical device
18. Patient with language barriers precluding adequate understanding or co-operation or who, in the opinion of the investigator, should not participate in the trial
19. Treatment with an investigational treatment within 30 days prior to randomization

20. Woman pregnant, nursing or of childbearing potential age without effective contraception methods* or intends to become pregnant.

    • an effective contraception method is defined as implants, oral oestro-progestative contraceptives or progestative which inhibit ovulation contraceptives (e.g, desogestrel), or double barrier method (condom plus spermicide or diaphragm plus spermicide) or levonorgestrel intrauterine devices, or vasectomized partner (confirmed with two negative spermograms).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PIMAVANSERIN; In this arm, each patient will take orally, once daily 2 tablets of active drug pimavanserin of 17mg each and this during the 8-weeks treatment period.	Drug: Active drug: pimavanserin 17mg (2 strength tablets); Pimavanserin 17mg (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8); Behavioral: Assessment of severity of ICD (impulse control disorders); Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8); Behavioral: Assessment of quality of life; Parkinson's Disease questionnaire (PDQ-39) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8); Behavioral: Assessment of depression; Montgomery-Åsberg Depression Rating Scale (MADRS) will be administrated at day 0 and day 56 (week 8); Behavioral: Assessment of cognition; Cognitive state of patients by Montreal Cognitive Assessment (MOCA) will be assessed at day 0.; Behavioral: Assessment of severity of Parkinson Disease; Clinical Global Impression Severity scale (CGIS) will be administrated at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16); Procedure: Blood analysis; Blood sample will be collected for analyse of safety (blood count/liver and kidney functions, electrolytes) at day 0 and day 56; Procedure: Cardiac monitoring; Electrocardiogram will be realized at day 0, 28 and 56.; Behavioral: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors; Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP, ISI, PDSS-2) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
Placebo Comparator: PLACEBO; In this arm, each patient will take orally, once daily, 2 tablets of matching placebo (containing all of the same excipients except for the active compound) and this during the 8-weeks treatment period.	Behavioral: Assessment of severity of ICD (impulse control disorders); Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8); Behavioral: Assessment of quality of life; Parkinson's Disease questionnaire (PDQ-39) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8); Behavioral: Assessment of depression; Montgomery-Åsberg Depression Rating Scale (MADRS) will be administrated at day 0 and day 56 (week 8); Behavioral: Assessment of cognition; Cognitive state of patients by Montreal Cognitive Assessment (MOCA) will be assessed at day 0.; Behavioral: Assessment of severity of Parkinson Disease; Clinical Global Impression Severity scale (CGIS) will be administrated at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16); Procedure: Blood analysis; Blood sample will be collected for analyse of safety (blood count/liver and kidney functions, electrolytes) at day 0 and day 56; Procedure: Cardiac monitoring; Electrocardiogram will be realized at day 0, 28 and 56.; Drug: Placebo: 2 tablets containing same excipients except active compound; Placebo (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8); Behavioral: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors; Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP, ISI, PDSS-2) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in ICD (Impulsive Control Disorders) severity after 8 weeks of treatment evaluated by QUestionnaire for Impulse-compulsive disorder in Parkinson's disease Rating Scale (QUIP-RS).	The primary endpoint of this study will be assessed in both arms using the total form of QUIP-RS. QUIP-RS has 4 primary questions (pertaining to commonly reported thoughts, urges/desires, and behaviors associated with ICDs), each applied to the 4 ICDs (compulsive gambling, buying, eating, and sexual behavior) and 3 related disorders (medication use, punding, and hobbyism). It uses a 5-point Likert scale (score 0-4 for each question) to gauge the frequency of behaviors. Scores for each ICD and related disorder range from 0 to 16 and the total QUIP-RS score for all ICDs and related disorders combined ranges from 0 to 112, with a higher score indicating greater severity (ie, frequency) of symptoms.	at day 0 and week 8

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change SCale for Outcomes in Parkinson's disease - Sleep (SCOPA-SLEEP) score after 4 and 8 weeks of treatment	The SCOPA-SLEEP is a specific Parkinson's disease rating scale for assessing nighttime sleep (NS) problems and daytime sleepiness (DS) in the past month. The NS subscale has 5 items, scored from 0 (not at all) to 3 (a lot). The DS subscale is composed of 6 items with response options ranging from 0 (never) to 3 (often) with a higher total score indicating greater severity of sleep problems.	At day 0, week 4 and week 8
Change in Movement Disorders Society-sponsored Unified Parkinson's Disease Rating scale (MDS-UPDRS) scores after 4 and 8 weeks of treatment	MDS-UPDRS is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease. The MDS-UPDRS has four parts, namely, I: Non-motor Experiences of Daily Living; II: Motor Experiences of Daily Living; III: Motor Examination; IV: Motor Complications. The four parts contains 64 items which are each rated on a scale of 0 (normal or no disease effect) to 4 (maximum negative effect). Negative changes from baseline values indicate improvement.	At day 0, week 4 and week 8
Change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores after 4 and 8 weeks of treatment	MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Each item yields a score of 0 to 6 and the overall score ranges from 0 to 60 with higher MADRS score indicating more severe depression.	At day 0, week 4 and week 8
Change in Ardouin's scale scores after 4 and 8 weeks of treatment	The Ardouin's scale is a validated instrument using a structured and standardised interview composed of 21 items specifically designed to assess mood and behaviour with a view to quantifying changes related to Parkinson's Disease, to dopaminergic medication, and to non-motor fluctuations. Each item is scored from 0 (absent) to 4 (severe).	At day 0, week 4 and week 8
Change in the rate of Clinical Global Impression Severity (CGIS) scale after 4, 8 and 16 weeks of treatment	Severity of PD will be assessed in both arms using CGIS scale: the CGI-S is a 7-point scale that requires the rating of the severity of the patient's illness at the time of assessment. Possible ratings are: 1: Normal, not at all ill; 2: Borderline mentally ill; 3: Mildly ill; 4: Moderately ill ; 5: Markedly ill; 6: Severely ill; 7: Among the most extremely ill patients	At day 0, week 4, week 8 and week 16
Change in ICD (Impulsive Control Disorders) severity after 4 weeks of treatment evaluated by QUIP-RS.	Global functioning and severity of the disease will be assessed in both arms by QUIP-RS has 4 primary questions each applied to the 4 ICDs and 3 related disorders It uses a 5-point Likert scale and a higher score indicating greater severity (ie, frequency) of symptoms.	At day 0 and week 4
Changes in quality of life measured by Parkinson's Disease Questionnaire (PDQ-39) scores after 4 and 8 weeks of treatment	Functioning and well-being of patients during the preceding month will be assessed in both arms by 39 questions of the self-administered Parkinson's Disease Questionnaire (PQD-39). Each question is scored from 0 (never) to 4 (always), the higher score indicating higher impact of illness in quality of life.	At day 0, week 4 and week 8
Change in Zarit scale scores after 4 and 8 weeks of treatment for caregivers	The burden of the patient's functional and behavioural worsening and to home care will be assessed to the caregiver in both arms by the Zarit Burden scale. It is composed of 22 items to measure the magnitude of the burden experienced by the caregiver. Each item is scored from 0 (never) to 4 (almost always). With a higher score indicating a greater load suffered by the caregiver.	At day 0, week 4 and week 8
Change SCale for Outcomes in Parkinson's disease - Sleep (Insomnia severity index) score after 4 and 8 weeks of treatment	Scale ranging from 0 to 28 with a higher total score indicating greater severity of sleep problems.	At day 0, week 4 and week 8
Change SCale for Outcomes in Parkinson's disease - Sleep (PDSS-2: Parkinson Disease Sleep Scale-2) score after 4 and 8 weeks of treatment	Scale ranging from 0 to 60 with a higher total score indicating greater severity of sleep problems.	At day 0, week 4 and week 8

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total number of adverse events and serious adverse events	Open-ended questionnaire will be used in both arms	At week 16

Collaborators and Investigators

• Sponsor: University Hospital, Strasbourg, France
• Collaborators: EUCLID Clinical Trial Platform; NS-PARK; F-CRIN
• Investigators: Principal Investigator: Mathieu ANHEIM, MD, CHRU Strasbourg

Study record dates

Study Major Dates

• Study Start (Actual): October 23, 2020
• Primary Completion (Anticipated): October 23, 2024
• Study Completion (Anticipated): December 23, 2024

Study Registration Dates

• First Submitted: May 7, 2019
• First Submitted That Met QC Criteria: May 10, 2019
• First Posted (Actual): May 13, 2019

Study Record Updates

• Last Update Posted (Actual): May 12, 2023
• Last Update Submitted That Met QC Criteria: May 9, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Keywords: Behavior; Dopamine agonist; impulse control disorders; pimavanserin; Serotoninergic 5-HT2A inverse agonist
• Additional Relevant MeSH Terms: Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Parkinson Disease; Disruptive, Impulse Control, and Conduct Disorders; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Antipsychotic Agents; Tranquilizing Agents; Psychotropic Drugs; Serotonin Agents; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Antiparkinson Agents; Anti-Dyskinesia Agents; Pimavanserin
• Other Study ID Numbers: 6398

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes